Biotech Companies Show Promising Clinical Progress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy MRNA?
Source: NASDAQ.COM
- Moderna's mRNA Platform: Moderna's mRNA vaccines are produced faster than traditional vaccines and elicit stronger immune responses, with shares up 73% in 2023, indicating potential for continued growth over the next five years despite clinical and regulatory risks.
- Personalized Cancer Vaccine: The mRNA-4157 candidate, when combined with Keytruda, significantly reduced recurrence or death risk in advanced melanoma patients, showcasing its potential across various cancer types and likely enhancing future market performance for Moderna.
- Abivax's Innovative Drug: Abivax's obefazimod achieved its primary endpoint of clinical remission in a phase 3 trial, with 47.3% of patients previously treated unsuccessfully, positioning it as a strong competitor in the ulcerative colitis market, challenging established players if approved.
- Market Potential and Risks: If Abivax secures approval for obefazimod and expands into related conditions, its sales could soar over the next five years, but investors should remain cautious of potential clinical trial setbacks that could impact stock performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
20 Analyst Rating
1 Buy
16 Hold
3 Sell
Hold
Current: 53.570
Low
17.00
Averages
32.47
High
63.00
Current: 53.570
Low
17.00
Averages
32.47
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Moderna Stock Drops 7.49% Amid Earnings Anticipation
- Stock Volatility: Moderna's stock closed at $49.56, reflecting a 7.49% decline from the previous day, which is less severe than the S&P 500's 1.67% drop, indicating market caution towards the biotech sector.
- Earnings Expectations: The company is projected to report an EPS of -$2.03, representing a 19.44% increase year-over-year, with quarterly revenue expected at $229.96 million, up 112.92% from the same period last year, highlighting significant revenue growth potential.
- Analyst Confidence: Recent adjustments to analyst earnings estimates for Moderna, despite a 1.69% decrease in the consensus EPS projection over the past month, typically indicate confidence in the company's future performance, which could influence short-term stock movements.
- Industry Ranking: Moderna operates within the Biomedical and Genetics industry, currently ranked 148 by Zacks, placing it in the bottom 40% of over 250 industries, suggesting overall underperformance that may negatively impact Moderna's market position.
See More
Moderna and Kodak Options Show High Trading Volume
- Surge in Moderna Options: Today, Moderna Inc's options volume reached 126,550 contracts, equivalent to approximately 12.7 million shares, representing a significant 141.5% of its average daily trading volume over the past month, indicating strong market interest in its future performance.
- High Call Option Activity: Within Moderna, the $53 strike call option has seen particularly high activity, with 17,074 contracts traded today, representing about 1.7 million shares, suggesting investor confidence in the stock's upward potential.
- Kodak Options Trading Overview: Eastman Kodak Co's options volume stands at 11,915 contracts, approximately 1.2 million shares, which is 108.2% of its average daily trading volume over the past month, reflecting market interest in its potential volatility.
- Kodak Call Option Activity: For Kodak, the $10 strike call option has recorded a trading volume of 4,162 contracts, representing around 416,200 shares, indicating investor expectations for future price increases.
See More
Investment Outlook for Healthcare Stocks
- Moderna's mRNA Platform: Moderna's mRNA vaccines are favored for their rapid production and strong immune responses, particularly with its flu vaccine seeking U.S. approval, which is expected to enhance market competitiveness and drive future growth.
- Personalized Cancer Vaccine Progress: The mRNA-4157, developed in partnership with Merck, shows promising results in significantly reducing recurrence or death risk in advanced melanoma patients, with five-year follow-up data indicating optimistic clinical prospects that could sustain stock price growth over the next five years.
- Abivax's Innovative Drug: Abivax's obefazimod demonstrates excellent efficacy in treating ulcerative colitis, with clinical trials showing that 47.3% of patients previously unresponsive to traditional treatments could benefit, positioning the company to challenge market giants and achieve sales growth if approved.
- Market Competition and Risks: While Abivax faces fierce competition from large pharmaceutical companies, the unique advantages of obefazimod may allow it to capture market share over the next five years; however, the risks associated with clinical trials require cautious consideration from investors.
See More
Biotech Companies Show Promising Clinical Progress
- Moderna's mRNA Platform: Moderna's mRNA vaccines are produced faster than traditional vaccines and elicit stronger immune responses, with shares up 73% in 2023, indicating potential for continued growth over the next five years despite clinical and regulatory risks.
- Personalized Cancer Vaccine: The mRNA-4157 candidate, when combined with Keytruda, significantly reduced recurrence or death risk in advanced melanoma patients, showcasing its potential across various cancer types and likely enhancing future market performance for Moderna.
- Abivax's Innovative Drug: Abivax's obefazimod achieved its primary endpoint of clinical remission in a phase 3 trial, with 47.3% of patients previously treated unsuccessfully, positioning it as a strong competitor in the ulcerative colitis market, challenging established players if approved.
- Market Potential and Risks: If Abivax secures approval for obefazimod and expands into related conditions, its sales could soar over the next five years, but investors should remain cautious of potential clinical trial setbacks that could impact stock performance.
See More
Trump Administration Delays Nomination for CDC Director
- Nomination Delay: The Trump administration has failed to nominate a new CDC director by the Wednesday deadline, resulting in NIH chief Jay Bhattacharya continuing to lead the CDC, although he will lose the acting director title.
- Candidate Vetting: According to The Washington Post, the White House is taking its time to vet about six candidates, indicating a cautious approach amid growing political and operational pressures in selecting CDC leadership.
- Candidate List: Cardiologist Joseph Marine from Johns Hopkins Medicine and former Kentucky Governor Ernie Fletcher are among the contenders, reflecting the diversity in potential candidates being considered by the administration.
- Historical Context: During Trump's second term, the CDC has primarily been led by acting directors, with former director Susan Monarez being fired for refusing to follow orders from HHS Secretary Robert F. Kennedy Jr., highlighting instability within CDC leadership.
See More
Moderna's Vaccine Business Recovery
- Revenue Recovery: Moderna generated over $18 billion from its COVID-19 vaccine in 2022, and despite a decline in demand leading to falling earnings, the company's stock has surged 70% as it diversifies its vaccine portfolio, indicating market confidence in its future potential.
- New Product Development: The company has secured approvals for a respiratory syncytial virus vaccine and a second COVID-19 vaccine, and it has submitted a flu vaccine candidate to regulators, which could provide new options for the upcoming flu season and enhance its competitive position.
- Oncology Potential: Moderna's late-stage cancer vaccine trials, particularly the fully enrolled Phase 3 melanoma trial, show promising prospects and are expected to be key growth drivers, expanding the company's footprint in oncology.
- Financial Challenges and Outlook: With projected revenue of $1.9 billion and a net loss of $2.8 billion for 2025, the company faces financial pressures; however, as new products reach the market, investors must remain patient for potential growth returns.
See More
Moderna Stock Drops 7.49% Amid Earnings Anticipation
- Stock Volatility: Moderna's stock closed at $49.56, reflecting a 7.49% decline from the previous day, which is less severe than the S&P 500's 1.67% drop, indicating market caution towards the biotech sector.
- Earnings Expectations: The company is projected to report an EPS of -$2.03, representing a 19.44% increase year-over-year, with quarterly revenue expected at $229.96 million, up 112.92% from the same period last year, highlighting significant revenue growth potential.
- Analyst Confidence: Recent adjustments to analyst earnings estimates for Moderna, despite a 1.69% decrease in the consensus EPS projection over the past month, typically indicate confidence in the company's future performance, which could influence short-term stock movements.
- Industry Ranking: Moderna operates within the Biomedical and Genetics industry, currently ranked 148 by Zacks, placing it in the bottom 40% of over 250 industries, suggesting overall underperformance that may negatively impact Moderna's market position.
See More
Moderna and Kodak Options Show High Trading Volume
- Surge in Moderna Options: Today, Moderna Inc's options volume reached 126,550 contracts, equivalent to approximately 12.7 million shares, representing a significant 141.5% of its average daily trading volume over the past month, indicating strong market interest in its future performance.
- High Call Option Activity: Within Moderna, the $53 strike call option has seen particularly high activity, with 17,074 contracts traded today, representing about 1.7 million shares, suggesting investor confidence in the stock's upward potential.
- Kodak Options Trading Overview: Eastman Kodak Co's options volume stands at 11,915 contracts, approximately 1.2 million shares, which is 108.2% of its average daily trading volume over the past month, reflecting market interest in its potential volatility.
- Kodak Call Option Activity: For Kodak, the $10 strike call option has recorded a trading volume of 4,162 contracts, representing around 416,200 shares, indicating investor expectations for future price increases.
See More
Investment Outlook for Healthcare Stocks
- Moderna's mRNA Platform: Moderna's mRNA vaccines are favored for their rapid production and strong immune responses, particularly with its flu vaccine seeking U.S. approval, which is expected to enhance market competitiveness and drive future growth.
- Personalized Cancer Vaccine Progress: The mRNA-4157, developed in partnership with Merck, shows promising results in significantly reducing recurrence or death risk in advanced melanoma patients, with five-year follow-up data indicating optimistic clinical prospects that could sustain stock price growth over the next five years.
- Abivax's Innovative Drug: Abivax's obefazimod demonstrates excellent efficacy in treating ulcerative colitis, with clinical trials showing that 47.3% of patients previously unresponsive to traditional treatments could benefit, positioning the company to challenge market giants and achieve sales growth if approved.
- Market Competition and Risks: While Abivax faces fierce competition from large pharmaceutical companies, the unique advantages of obefazimod may allow it to capture market share over the next five years; however, the risks associated with clinical trials require cautious consideration from investors.
See More
Biotech Companies Show Promising Clinical Progress
- Moderna's mRNA Platform: Moderna's mRNA vaccines are produced faster than traditional vaccines and elicit stronger immune responses, with shares up 73% in 2023, indicating potential for continued growth over the next five years despite clinical and regulatory risks.
- Personalized Cancer Vaccine: The mRNA-4157 candidate, when combined with Keytruda, significantly reduced recurrence or death risk in advanced melanoma patients, showcasing its potential across various cancer types and likely enhancing future market performance for Moderna.
- Abivax's Innovative Drug: Abivax's obefazimod achieved its primary endpoint of clinical remission in a phase 3 trial, with 47.3% of patients previously treated unsuccessfully, positioning it as a strong competitor in the ulcerative colitis market, challenging established players if approved.
- Market Potential and Risks: If Abivax secures approval for obefazimod and expands into related conditions, its sales could soar over the next five years, but investors should remain cautious of potential clinical trial setbacks that could impact stock performance.
See More
Trump Administration Delays Nomination for CDC Director
- Nomination Delay: The Trump administration has failed to nominate a new CDC director by the Wednesday deadline, resulting in NIH chief Jay Bhattacharya continuing to lead the CDC, although he will lose the acting director title.
- Candidate Vetting: According to The Washington Post, the White House is taking its time to vet about six candidates, indicating a cautious approach amid growing political and operational pressures in selecting CDC leadership.
- Candidate List: Cardiologist Joseph Marine from Johns Hopkins Medicine and former Kentucky Governor Ernie Fletcher are among the contenders, reflecting the diversity in potential candidates being considered by the administration.
- Historical Context: During Trump's second term, the CDC has primarily been led by acting directors, with former director Susan Monarez being fired for refusing to follow orders from HHS Secretary Robert F. Kennedy Jr., highlighting instability within CDC leadership.
See More
Moderna's Vaccine Business Recovery
- Revenue Recovery: Moderna generated over $18 billion from its COVID-19 vaccine in 2022, and despite a decline in demand leading to falling earnings, the company's stock has surged 70% as it diversifies its vaccine portfolio, indicating market confidence in its future potential.
- New Product Development: The company has secured approvals for a respiratory syncytial virus vaccine and a second COVID-19 vaccine, and it has submitted a flu vaccine candidate to regulators, which could provide new options for the upcoming flu season and enhance its competitive position.
- Oncology Potential: Moderna's late-stage cancer vaccine trials, particularly the fully enrolled Phase 3 melanoma trial, show promising prospects and are expected to be key growth drivers, expanding the company's footprint in oncology.
- Financial Challenges and Outlook: With projected revenue of $1.9 billion and a net loss of $2.8 billion for 2025, the company faces financial pressures; however, as new products reach the market, investors must remain patient for potential growth returns.
See More
